Is MNKD a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

6,150 people get MNKD articles and Market Currents by email alert.

Get email alerts on MNKD »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

MannKind: Facts And Fundamentals Over Fiction And Fear
George Rho • Wed, Jun 19 • 52 Comments
Pricing MannKind Corporation On A Stand-Alone Basis
George Rho • Wed, Jun 12 • 53 Comments
Can MannKind Deliver A Summer Blockbuster?
Red Bull • Tue, Jun 11 • 35 Comments
MannKind: It All Comes Down To This
Brett Moll • Tue, Jun 4 • 73 Comments
MannKind's Afrezza And The Oramed Threat
Cory Renauer • Thu, May 23 • 29 Comments
Pricing A Highly Probable Takeover Of MannKind
George Rho • Wed, May 22 • 108 Comments
Why MannKind's Afrezza Will Succeed Where Pfizer Failed
Cory Renauer • Sat, May 18 • 32 Comments
MannKind's Afrezza Likely To Easily Gain Approval
Joe Springer • Mon, Apr 15 • 159 Comments
MannKind's Afrezza Likely To Fail AFFINITY 1 Phase III Trial
Brian L. Wilson • Thu, Apr 11 • 114 Comments
MannKind: A Pure Speculative Bet
Efsinvestment • Wed, Mar 20 • 51 Comments
5 Reasons MannKind Could Be The Best Performing Stock Of 2013
Joe Springer • Fri, Mar 8 • 220 Comments
An Excellent Biotech Bet For 2013
Stock Whisper • Wed, Dec 26, 2012 • 6 Comments
Long Mannkind? How To Make Money While In Queue
Clayton Rulli • Fri, Dec 21, 2012 • 2 Comments
3 Ways To Trade MannKind - Given 2013 Will Be A Huge Success Or A Complete Failure
Rodney Watson • Tue, Dec 18, 2012 • 27 Comments
Long MannKind's Afrezza: Shares Versus A Bull Call Spread
Clayton Rulli • Sat, Dec 1, 2012 • 45 Comments
With Share Offering Registration And Trial Enrollment Complete, Time To Buy MannKind
Rx Stocks • Fri, Oct 12, 2012 • 16 Comments
3 Reasons This Speculative Bio-Pharma Is A Winner
Joe Springer • Fri, Aug 10, 2012 • 77 Comments
MannKind Fights On With Its Diabetes Game-Changer Afrezza
Praveen Jayarajan • Fri, Jul 6, 2012 • 31 Comments
MannKind: If You Buy, When?
Rx Stocks • Wed, Jun 27, 2012 • 14 Comments
Why Mannkind Has Long-Term Value
Spencer Knight • Wed, May 23, 2012 • 10 Comments

5 Reasons MannKind Could Be The Best Performing Stock Of 2013
Joe Springer • Fri, Mar 8 • 220 Comments

Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market
StockMatusow • Tue, Jun 18 • 33 Comments
For Love And Money: 3 Growth Stocks From Casey's Alex Daley
Life Sciences Report • Fri, Jun 14 • 4 Comments
This Under-The-Radar Diabetes Stock Has Significant Upside Potential
Shane Blackmon • Tue, Jun 11 • 8 Comments
Social Networking Stocks Faltering And The Volatile Biotechs
Matthew Smith • Tue, Jun 4
Clovis Among Top Small-Cap Biotech Picks By Legendary Fund Managers In Q1/2013
GuruFundPicks • Tue, Jun 4
Aegerion And Other Top Small-Cap Biotech Buys By Mega Funds In March 2013 Quarter
GuruFundPicks • Mon, Jun 3 • 2 Comments
Insiders Are Buying These 3 Rallying Biotech Stocks
Kapitall • Sun, Jun 2 • 1 Comment
Arena Buyout More 'Highly Probable' Than MannKind
Chris_Roberts • Thu, May 23 • 36 Comments
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 77 Comments
Insiders Are Buying These 9 Environmentally Conscious Stocks
Kapitall • Fri, Apr 26
Bullish Insider Buying Activity Surfacing Among These Names In Real Estate, Healthcare
Insightful Investor • Tue, Apr 16 • 8 Comments
Healthcare Sector Trends May Be Shifting Towards Boutique Pharmacy Services
VFC's Stock House • Tue, Apr 16 • 3 Comments
2 Biotechs With A Strong Risk Of Failure
Equity Options Guru • Sun, Apr 14 • 74 Comments
Minimizing Risk When Investing In Biopharmas
Healthcare Specialist • Wed, Apr 10 • 17 Comments
Tech And Healthcare: Eye Catching Themes Of Early April
D. Mero • Tue, Apr 9 • 17 Comments
3 Biopharmas With Significant Potential
Healthcare Specialist • Thu, Apr 4 • 21 Comments
My 2Q 2013 Diversified REIT Portfolio Designed For Outperformance
Dane Bowler • Wed, Apr 3 • 34 Comments
Biotech: Hedging While Speculating
Nathaniel Munson • Fri, Mar 29 • 36 Comments
Several Big Growth Stories In Biotech: Keith Markey
Life Sciences Report • Thu, Mar 28 • 5 Comments
Cramer's Mad Money - Whoever Loses The Dell Bidding War Is The Winner (3/26/13)
SA Editor Miriam Metzinger • Wed, Mar 27 • 1 Comment

MannKind Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9 • 7 Comments
MannKind Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Feb 11 • 2 Comments
MannKind Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 1, 2012
MannKind's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 8, 2012
MannKind's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Wed, May 9, 2012 • 5 Comments
MannKind's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Feb 22, 2012
MannKind's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Nov 4, 2011
MannKind's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Aug 5, 2011
MannKind's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Mon, May 9, 2011 • 3 Comments
MannKind CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Feb 10, 2011
MannKind CEO Discusses Q3 2010 Results – Earnings Call Transcript
Fri, Oct 29, 2010
Mannkind Corp. Q2 2010 Earnings Call Transcript
Mon, Aug 2, 2010 • 4 Comments
MannKind Corporation Q1 2010 Earnings Call Transcript
Fri, Apr 30, 2010
MannKind Corporation Q4 2009 Earnings Call Transcript
Tue, Feb 2, 2010 • 2 Comments
MannKind Corporation Q3 2009 Earnings Call Transcript
Mon, Nov 2, 2009
MannKind Corporation Q2 2009 Earnings Call Transcript
Mon, Aug 3, 2009
MannKind Corporation F1Q09 Earnings Call Transcript
Mon, May 4, 2009 • 2 Comments
MannKind Corporation Q4 2008 Earnings Call Transcript
Tue, Feb 17, 2009
MannKind Corporation Q3 2008 Earnings Call Transcript
Wed, Nov 5, 2008
MannKind Corporation Q2 2008 Earnings Call Transcript
Mon, Aug 11, 2008

MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes

Business Wire (Mon, 8:00AM)
MannKind to Present at Wells Fargo Securities Research & Economics 2013 Healthcare Conference

Business Wire (Jun 11, 2013)
MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes

Business Wire (May 31, 2013)
MannKind to Present at Jefferies 2013 Global Healthcare Conference

Business Wire (May 29, 2013)
MannKind Corporation Reports 2013 First Quarter Financial Results

Business Wire (May 9, 2013)
MannKind to Present at Bank of America Merrill Lynch 2013 Health Care Conference

Business Wire (May 8, 2013)
MannKind Corporation to Hold 2013 First Quarter Financial Results Conference Call on May 9, 2013

Business Wire (May 2, 2013)
MannKind Corporation to Present at the Cowen and Company 33rd Annual Health Care Conference

Business Wire (Feb 26, 2013)
MannKind Corporation Reports 2012 Fourth Quarter and Full Year Financial Results

Business Wire (Feb 11, 2013)
MannKind Corporation to Hold 2012 Fourth Quarter and Full Year Financial Results Conference Call on February 11, 2013

Business Wire (Feb 4, 2013)
MannKind Corporation to Present at The 31st Annual J.P. Morgan Healthcare Conference

Business Wire (Jan 3, 2013)
MannKind Corporation to Present at The 24th Annual Piper Jaffray Healthcare Conference

Business Wire (Nov 20, 2012)
Colby and MannKind Sign License and Joint Development Agreement to Develop and Commercialize Cancer Immunotherapy Products

Business Wire (Nov 13, 2012)
MannKind Corporation Reports 2012 Third Quarter Financial Results

Business Wire (Nov 1, 2012)
MannKind Corporation Reschedules 2012 Third Quarter Financial Results Conference Call to November 1, 2012 Due to Hurricane Sandy

Business Wire (Oct 29, 2012)
MannKind Corporation to Hold 2012 Third Quarter Financial Results Conference Call on October 29, 2012

Business Wire (Oct 22, 2012)
MannKind Announces Pricing of Public Offering of Common Stock and Warrants

Business Wire (Oct 18, 2012)
MannKind Receives Commitment from The Mann Group to Acquire 40,000,000 Shares of Common Stock and Warrants to Purchase Common Stock

Business Wire (Oct 18, 2012)
MannKind Announces Proposed Public Offering of Common Stock and Warrants

Business Wire (Oct 17, 2012)
MannKind Completes Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA

Business Wire (Oct 5, 2012)

MNKD vs. ETF Alternatives

Company Description

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead product candidate, AFRESA, is an ultra rapid-acting insulin that has completed Phase 3 clinical trials... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 18, 12:45 PM Midday top 10 gainers: USMD +31%. ZN +26%. GEVO +23%. CBMX +21%. CYTK +20%. PRXI +18%. HOTR +18%. WLT +15%. BBGI +15%. ATV +14%.
Midday top 10 Losers: OSH -14%. MNKD -13%. OPXA -12%. LTON -10%. IESC -10%. KNDI -9%. FRO -8%. GENE -8%. BAA -8%. HAST -8%. Comment! [On the Move]
Tuesday, June 18, 12:44 PM MannKind (MNKD -12%) takes a hit today on no specific new-related driver. Speculation is circulating that a number of hedge funds are leaning on the shares to flush out supply from retail investors. 9 Comments [Healthcare, On the Move]
Monday, June 17, 9:11 AM Premarket gainers: OSH +47%. FRO +21%. KNDI +16%. LDK +8%. MNKD +5%. AMD +5%. DVAX +5%. NFLX +5%.
Losers: FOLD -29%. TEX -14%. MDVN -7%. Comment! [On the Move]
Monday, June 17, 8:49 AM MannKind (MNKD) says a Phase 3 trial of Afrezza in patients with type 2 diabetes is complete. Shares are +4% premarket. The company plans to report data from the trial later in the summer. (PR) 2 Comments [Healthcare]
Friday, June 7, 10:12 AM More on BofA's MannKind (MNKD -0.7%) downgrade: Price target raised to $8 from $5 as "model adjustments" raise the output from the bank's discounted cash flow calculation. Analyst Steve Byrne notes that while he "continues to expect favorable phase 3 data in coming months … the shares as fairly valued." Byrne also says his "penetration forecasts for Afrezza in Type 1 and 2 patients are unchanged." 3 Comments [Healthcare]
Friday, June 7, 10:11 AM More on BofA's MannKind (MNKD -0.7%) downgrade: Price target raised to $8 from $5 as "model adjustments" raise the output from the bank's discounted cash flow calculation. Analyst Steve Byrne notes that while he "continues to expect favorable phase 3 data in coming months … the shares as fairly valued." Byrne also says his "penetration forecasts for Afrezza in Type 1 and 2 patients are unchanged." Comment! [Healthcare]
Friday, June 7, 7:23 AM BofA downgrades MannKind (MNKD) to Neutral from Buy. More details as they come in. For those who can't get enough of the Afrezza debate, see SA contributor Brett Moll's recent article. 4 Comments [Healthcare]
Friday, May 31, 4:17 PM MannKind (MNKD +1.2%) says it's completed all follow-ups for patients enrolled in Phase 3 clinical studies of its diabetes drug Afrezza, an investigational, rapid-acting mealtime insulin therapy administered by inhaler. The company expects to release data from this study later this summer. 2 Comments [Healthcare]
Wednesday, May 22, 12:52 PM Midday top 10 gainers: CLNT +125%. MBND +24%. ZLC +24%. RCON +22%. MNKD +15%. NOA +15%. INSM +15%. SGOC +19%. CETV +14%. SKS +14%.
Midday top 10 Losers: STP -17%. LDK -14%. SWI -12%. MLP -11%. FXEN -12%. LAKE -10%. BALT -10%. DQ -10%. CSUN -9%. AMAG -9%. Comment! [On the Move]
Wednesday, May 22, 12:47 PM A takeover of MannKind (MNKD +15.9%) is "highly probable" SA contributor George Rho says, in an article published this morning which suggests $27.50/share as a ballpark figure (that's a 413% upside from Tuesday's close if you're inclined to keep score). Rho also notes that his "assumptions and projections would have to be considerably off the mark for the stock not to have substantial upside potential." Meanwhile, in the options market, an investor rolled a short position in January $5 strike calls up to the January $9 strike — 31K contracts traded at those two strikes this morning. Comment! [On the Move, Healthcare]
Wednesday, May 15, 12:04 PM MannKind Corporation (MNKD +6.4%) moves up again today after being initiated by MLV & Co. with a Buy and a $6 price target. The stock has been on a tear over the past few days, gaining over 25% since Friday on the back of in-line earnings report and positive comments out of its management on the progress of its Afrezza trials. Read more here: Earnings Call Transcript. 1 Comment [Healthcare, On the Move]
Friday, May 10, 3:50 PM For Mankind (MNKD +10.3%) no bad news is good news today, as the stock rips higher following an inline Q1 report late yesterday. Operating expenses rose by 9% Y/Y, primarily due to an increase in clinical trial related expenses. 2 Comments [Healthcare, Earnings, On the Move]
Thursday, May 9, 6:05 PM MannKind (MNKD): Q1 EPS of -$0.15 in-line. Shares +2.3% AH. (PR) 2 Comments [Earnings, Breaking News, Healthcare, On the Move]
Friday, April 12, 9:10 AM Premarket gainers: FST +12%. IOC +8%. WLT +7%. ASH +5%.
Losers: INFY -18%. HIMX -9%. MNKD -8%. Comment! [On the Move]
Friday, April 12, 8:14 AM Shares of Mannkind (MNKD) trade notably lower before the bell. In an article published Thursday evening, SA contributor Brian Wilson questions whether the company's key drug Afrezza can pass muster in Phase III clinicals. Shares -6.27% premarket. (The bullish thesis: Afrezza could be first-line therapy) 2 Comments [On the Move]
Friday, March 8, 8:17 AM MannKind (MNKD) gains 1.8% premarket as SA Pro author Joe Springer's bullish piece exits embargo. The company's Afrezza, currently in Phase III trials, could be the first-line drug therapy for type 2 diabetes - a disease now of pandemic size, he writes. 2 Comments [Healthcare, On the Move]

Stockexpertpro
Long $MNKD 10K Shares
8 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ChrisWestLA
from Fly On The Wall: MannKind CFO says has 'no news' to account for today's stock movement $MNKD http://bit.ly/11wjdrw
Tue, 4:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

k.dre
from streetinsider on $MNKD: traders speculate that hedge funds orchestrated a bear-raid to flush out weak-handed retail stock owners.
Tue, 2:02 PM
Reply (1)

• !Report Abuse
View all 1 replies
Chemist357: duh.it will happen a few times before results. Would not be surprised if a hit piece about bad data once august approches.
Tue, 2:40 PM
• !Report Abuse
Add a reply...

140 characters

p3z
$MNKD, down 20%, anyone have news?
Tue, 11:48 AM
Reply (4)

• !Report Abuse
View all 4 replies
joebat: I bought more at 6.31 :-)
Tue, 12:31 PM
• !Report Abuse
ChrisWestLA: May just be a massive "sell on good news" following the completion of the second trial.
Tue, 4:25 PM
• !Report Abuse
Add a reply...

140 characters

cnolz
Hoping for good Trial Results. Todays article gave us a beating $MNKD
Tue, 11:48 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

futureguy
in @ 6.32 $MNKD
Tue, 11:37 AM
Reply (2)

• !Report Abuse
View all 2 replies
joebat: I'm with ya.. 6.31
Tue, 11:42 AM
• !Report Abuse
futureguy: that was perfect timing by us Joebat :)
Tue, 1:21 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD - Don't know what to say except it looks like a buying opp...
Tue, 11:27 AM
Reply (14)

• !Report Abuse
View all 14 replies
sheldond: Joe, missed you buddy. I think anyone who thought they wouldn't shake the tree is crazy. I'm still holding my core free $$$rides
Tue, 4:57 PM
• !Report Abuse
sheldond: and a nice bounce back.....life is good when you have little fear and less risk
6 hours ago
• !Report Abuse
Add a reply...

140 characters

Mr.Fripple
hmmmm, trials done $MNKD down 16% someone see the results?
Tue, 11:15 AM
Reply (6)

• !Report Abuse
View all 6 replies
Mr.Fripple: to call it an article seems generous, if thats really all it takes to tank this stock ill start writing them so i can buy more.
Tue, 11:36 AM
• !Report Abuse
joebat: Someone also pointed to a MNKD reference in a SA article by Scott Matusow this morning. Once again, doesnt say much.
Tue, 11:56 AM
• !Report Abuse
Add a reply...

140 characters

pra
I'm new to $MNKD. Seek input from $MNKD followers. Has Afreeza approval already priced in fully ? Stock moved from $2 in Nov 2012 to $6.33.
Tue, 11:11 AM
Reply (4)

• !Report Abuse
View all 4 replies
ChrisWestLA: No way MF could move the stock like that with a milktoast article-SA published something not to long ago valuing stock potential around $28
Tue, 4:25 PM
• !Report Abuse
ChrisWestLA: No way MF could move the stock like that with a milktoast article-SA published something not to long ago valuing stock potential around $28
Tue, 4:25 PM
• !Report Abuse
Add a reply...

140 characters

doc321
$MNKD not news but targeting type 2 patients uncontrolled on metformin and who don't want to inject is a huge market- i treat - every day.
Mon, 10:33 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Seacap
$MNKD Short squeeze today...
Mon, 8:51 AM
Reply (2)

• !Report Abuse
View all 2 replies
Fincher: I am not sure. Ph 3 finish was anticipated- no catalyst. Everyone is now waiting for the results. I am very curious how this will end up.
Mon, 10:01 AM
• !Report Abuse
Seacap: You were correct. Would sure like to know why $MNKD fell apart today.
Tue, 6:05 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD - Don't know what to say except it looks like a buying opp...
Tue, 11:27 AM
Reply (14)

• !Report Abuse
View all 14 replies
sheldond: Joe, missed you buddy. I think anyone who thought they wouldn't shake the tree is crazy. I'm still holding my core free $$$rides
Tue, 4:57 PM
• !Report Abuse
sheldond: and a nice bounce back.....life is good when you have little fear and less risk
6 hours ago
• !Report Abuse
Add a reply...

140 characters

pra
I'm new to $MNKD. Seek input from $MNKD followers. Has Afreeza approval already priced in fully ? Stock moved from $2 in Nov 2012 to $6.33.
Tue, 11:11 AM
Reply (4)

• !Report Abuse
View all 4 replies
ChrisWestLA: No way MF could move the stock like that with a milktoast article-SA published something not to long ago valuing stock potential around $28
Tue, 4:25 PM
• !Report Abuse
ChrisWestLA: No way MF could move the stock like that with a milktoast article-SA published something not to long ago valuing stock potential around $28
Tue, 4:25 PM
• !Report Abuse
Add a reply...

140 characters

p3z
$MNKD, down 20%, anyone have news?
Tue, 11:48 AM
Reply (4)

• !Report Abuse
View all 4 replies
joebat: I bought more at 6.31 :-)
Tue, 12:31 PM
• !Report Abuse
ChrisWestLA: May just be a massive "sell on good news" following the completion of the second trial.
Tue, 4:25 PM
• !Report Abuse
Add a reply...

140 characters

k.dre
from streetinsider on $MNKD: traders speculate that hedge funds orchestrated a bear-raid to flush out weak-handed retail stock owners.
Tue, 2:02 PM
Reply (1)

• !Report Abuse
View all 1 replies
Chemist357: duh.it will happen a few times before results. Would not be surprised if a hit piece about bad data once august approches.
Tue, 2:40 PM
• !Report Abuse
Add a reply...

140 characters

futureguy
in @ 6.32 $MNKD
Tue, 11:37 AM
Reply (2)

• !Report Abuse
View all 2 replies
joebat: I'm with ya.. 6.31
Tue, 11:42 AM
• !Report Abuse
futureguy: that was perfect timing by us Joebat :)
Tue, 1:21 PM
• !Report Abuse
Add a reply...

140 characters

Mr.Fripple
hmmmm, trials done $MNKD down 16% someone see the results?
Tue, 11:15 AM
Reply (6)

• !Report Abuse
View all 6 replies
Mr.Fripple: to call it an article seems generous, if thats really all it takes to tank this stock ill start writing them so i can buy more.
Tue, 11:36 AM
• !Report Abuse
joebat: Someone also pointed to a MNKD reference in a SA article by Scott Matusow this morning. Once again, doesnt say much.
Tue, 11:56 AM
• !Report Abuse
Add a reply...

140 characters

sheldond
$MNKD seriously considering the flip about now..........will pull the trigger with half and watch.
Jun 10, 9:29 AM
Reply (5)

• !Report Abuse
View all 5 replies
sheldond: Great call chemist. I agree. I took a little off but was up over 325% still holding shares through FDA! Every 3% adds up....
Jun 10, 4:32 PM
• !Report Abuse
Chemist357: Nice, I have been with Mannkind for years, so I had to buy on the way down...so only 202% for me...
Jun 11, 10:11 AM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD and $HYGS new 52 week highs : ) http://bit.ly/1098KoL
Jun 4, 7:30 PM
Reply (11)

• !Report Abuse
View all 11 replies
Dennis R. Mahon: Well Gee... new 52 week high today... HooRay!
Jun 10, 3:11 PM
• !Report Abuse
Dennis R. Mahon: That would be HYGS... 52 week high... MNKD also doing welll...
Jun 10, 3:47 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
New 52 week highs for $HYGS and $MNKD Email joespringernews@gmail.com to be added to my free newsletter.
Jun 3, 3:06 PM
Reply (12)

• !Report Abuse
View all 12 replies
goinglong2020: Hey Joe - did you send a newsletter recently? I'm not sure I received it. Thanks!
Jun 3, 11:38 PM
• !Report Abuse
mmaps@yahoo.com: Thanks Joe, I am long for HYGS after reading your article. Your the MAN...
Jun 4, 1:54 AM
• !Report Abuse
Add a reply...

140 characters

Clayton Rulli
$MNKD is a monster
Jun 3, 12:03 PM
Reply (3)

• !Report Abuse
View all 3 replies
Clayton Rulli: nice GB! might want to check out sleling covered calls on a bounce... the premium is super juicy
Jun 3, 12:45 PM
• !Report Abuse
gbstern13: thnks clay
Jun 3, 1:22 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD Pretty sure that's a 52 week high : )
May 22, 10:47 AM
Reply (40)

• !Report Abuse
View all 40 replies
Icicle: Joe, with all the corruption at the FDA, wouldn't a buyout by a big name improve Afrezza's chances?
May 24, 9:29 AM
• !Report Abuse
Joe Springer: That is what some think..
May 24, 10:48 AM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD - That's a double. Just Sayin : ) http://seekingalpha.com/a/qw1h http://bit.ly/1098KoL
May 17, 10:59 AM
Reply (26)

• !Report Abuse
View all 26 replies
sheldond: Rule number one.....don't lose capital....same as rule two
May 21, 9:23 AM
• !Report Abuse
Nathaniel Munson: i agree with you on the core positions one absolutely, but you're right, biotech needs its own special rules
May 21, 9:33 AM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD $4.56 in the after hours - new 52 week high!
May 10, 6:30 PM
Reply (11)

• !Report Abuse
View all 11 replies
Joe Springer: I think that's where they make a deal this year.
May 12, 5:07 PM
• !Report Abuse
retpdguy: Joe. You ok.
May 15, 8:00 PM
• !Report Abuse
Add a reply...

140 characters

sheldond
$MNKD swing traders looking to take it to $6, MNKD meeting with BAC investors plus large short interest equals good things for long......
May 15, 9:30 AM
Reply (7)

• !Report Abuse
View all 7 replies
sheldond: Lets see what happens from the conference and if we can hold five.
May 15, 11:00 AM
• !Report Abuse
sheldond: There were a ton of penny grabbers this morning.
May 15, 11:02 AM
• !Report Abuse
Add a reply...

140 characters

MNKD MannKind Corporation

MNKD

MannKind Corporation